SCHEMBL7204042

SCHEMBL7204042

CCOC(=O)CC1=COc2ccc(OC)cc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
PPARG P37231 1/20 0.41
PTGS2 P35354 1/20 0.40
MAOB P27338 2/20 0.40
MTNR1A P48039 1/20 0.39
KDM4E B2RXH2 6/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 6/20 0.39
HPGD P15428 6/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199039 0.89 ALDH1A1 (0.40) MTNR1AKDM4EKMT2AMEN1ALDH1A1
SCHEMBL7205599 0.84 EGFR (0.43) MAOBKDM4EKMT2AMEN1ALDH1A1
SCHEMBL8113907 0.84 AKR1C2 (0.47) MTNR1AKDM4EALDH1A1HPGDMAPT
SCHEMBL8580296 0.76 MAOB (0.49) PTGS2MAOBMTNR1AKDM4EKMT2A
SCHEMBL7201899 0.75 MTNR1A (0.56) MTNR1ACYP1A2SMN1; SMN2
SCHEMBL7199329 0.75 LOXL2 (0.36) MAOBMTNR1AKDM4EKMT2AMEN1
SCHEMBL7198759 0.71 MTNR1A (0.52) MTNR1AKDM4EALDH1A1CYP1A2HSD17B10
SCHEMBL7201722 0.71 KDM4E (0.42) TSHRPTGS2MTNR1AKDM4EALDH1A1
SCHEMBL7203116 0.70 SMN1; SMN2 (0.43) TSHRPPARGMTNR1AKDM4EALDH1A1
SCHEMBL12093646 0.69 PPARG (0.48) TSHRPPARGPTGS2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 TSHR 263/4885PPARG 620/4885PTGS2 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.